99 related articles for article (PubMed ID: 27628763)
1. Warfarin use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.
Kinnunen PT; Murtola TJ; Talala K; Taari K; Tammela TL; Auvinen A
Scand J Urol; 2016 Dec; 50(6):413-419. PubMed ID: 27628763
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer-specific survival among warfarin users in the Finnish Randomized Study of Screening for Prostate Cancer.
Kinnunen PTT; Murtola TJ; Talala K; Taari K; Tammela TLJ; Auvinen A
BMC Cancer; 2017 Aug; 17(1):585. PubMed ID: 28851310
[TBL] [Abstract][Full Text] [Related]
3. Antidiabetic drug use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.
Haring A; Murtola TJ; Talala K; Taari K; Tammela TL; Auvinen A
Scand J Urol; 2017 Feb; 51(1):5-12. PubMed ID: 28084175
[TBL] [Abstract][Full Text] [Related]
4. Serum cholesterol and prostate cancer risk in the Finnish randomized study of screening for prostate cancer.
Murtola TJ; Kasurinen TVJ; Talala K; Taari K; Tammela TLJ; Auvinen A
Prostate Cancer Prostatic Dis; 2019 Mar; 22(1):66-76. PubMed ID: 30214034
[TBL] [Abstract][Full Text] [Related]
5. Anticoagulants and cancer mortality in the Finnish randomized study of screening for prostate cancer.
Kinnunen PTT; Murtola TJ; Talala K; Taari K; Tammela TLJ; Auvinen A
Cancer Causes Control; 2019 Aug; 30(8):877-888. PubMed ID: 31209595
[TBL] [Abstract][Full Text] [Related]
6. Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial.
Yli-Hemminki TH; Laurila M; Auvinen A; Määttänen L; Huhtala H; Tammela TL; Kujala PM
BJU Int; 2013 Oct; 112(6):735-41. PubMed ID: 23746332
[TBL] [Abstract][Full Text] [Related]
7. Allopurinol and the risk of prostate cancer in a Finnish population-based cohort.
Kukko V; Kaipia A; Talala K; Taari K; Tammela TLJ; Auvinen A; Murtola TJ
Prostate Cancer Prostatic Dis; 2019 Sep; 22(3):483-490. PubMed ID: 30696944
[TBL] [Abstract][Full Text] [Related]
8. Postscreening follow-up of the Finnish Prostate Cancer Screening Trial on putative prostate cancer risk factors: vitamin and mineral use, male pattern baldness, pubertal development and non-steroidal anti-inflammatory drug use.
Sarre S; Määttänen L; Tammela TL; Auvinen A; Murtola TJ
Scand J Urol; 2016 Aug; 50(4):267-73. PubMed ID: 26927237
[TBL] [Abstract][Full Text] [Related]
9. Prostate cancer and PSA among statin users in the Finnish prostate cancer screening trial.
Murtola TJ; Tammela TL; Määttänen L; Huhtala H; Platz EA; Ala-Opas M; Stenman UH; Auvinen A
Int J Cancer; 2010 Oct; 127(7):1650-9. PubMed ID: 20073066
[TBL] [Abstract][Full Text] [Related]
10. 5-Alpha reductase inhibitor use and prostate cancer survival in the Finnish Prostate Cancer Screening Trial.
Murtola TJ; Karppa EK; Taari K; Talala K; Tammela TL; Auvinen A
Int J Cancer; 2016 Jun; 138(12):2820-8. PubMed ID: 26804670
[TBL] [Abstract][Full Text] [Related]
11. The effect of warfarin use on clinical stage and histological grade of prostate cancer.
Tagalakis V; Tamim H
Pharmacoepidemiol Drug Saf; 2010 May; 19(5):436-9. PubMed ID: 20437456
[TBL] [Abstract][Full Text] [Related]
12. Prostate cancer risk among users of digoxin and other antiarrhythmic drugs in the Finnish Prostate Cancer Screening Trial.
Kaapu KJ; Murtola TJ; Määttänen L; Talala K; Taari K; Tammela TL; Auvinen A
Cancer Causes Control; 2016 Feb; 27(2):157-64. PubMed ID: 26573846
[TBL] [Abstract][Full Text] [Related]
13. Antiepileptic drugs and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.
Salminen JK; Kuoppamäki V; Talala K; Taari K; Mäkinen J; Peltola J; Tammela TLJ; Auvinen A; Murtola TJ
Int J Cancer; 2021 Jul; 149(2):307-315. PubMed ID: 33634851
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of prostate cancer screening among men using antidiabetic medication.
Vettenranta A; Murtola TJ; Talala K; Taari K; Stenman UH; Tammela TLJ; Auvinen A
Sci Rep; 2021 Apr; 11(1):7363. PubMed ID: 33795720
[TBL] [Abstract][Full Text] [Related]
15. Fasting blood glucose, glycaemic control and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.
Murtola TJ; Vihervuori VJ; Lahtela J; Talala K; Taari K; Tammela TL; Auvinen A
Br J Cancer; 2018 May; 118(9):1248-1254. PubMed ID: 29563633
[TBL] [Abstract][Full Text] [Related]
16. Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.
Zhu X; van Leeuwen PJ; Bul M; Otto SJ; de Koning HJ; Bangma CH; Schröder FH; Roobol MJ
Eur Urol; 2011 Aug; 60(2):330-6. PubMed ID: 21601352
[TBL] [Abstract][Full Text] [Related]
17. Towards an optimal interval for prostate cancer screening.
van Leeuwen PJ; Roobol MJ; Kranse R; Zappa M; Carlsson S; Bul M; Zhu X; Bangma CH; Schröder FH; Hugosson J
Eur Urol; 2012 Jan; 61(1):171-6. PubMed ID: 21840117
[TBL] [Abstract][Full Text] [Related]
18. The impact of interscreening interval and age on prostate cancer screening with prostate-specific antigen.
Wu GH; Auvinen A; Yen AM; Hakama M; Tammela TL; Stenman UH; Kujala P; Ruutu M; Chen HH
Eur Urol; 2012 May; 61(5):1011-8. PubMed ID: 22264679
[TBL] [Abstract][Full Text] [Related]
19. Risk of prostate cancer death in long-term users of warfarin: a population-based case-control study.
Tagalakis V; Tamim H; Blostein M; Hanley JA; Kahn SR
Cancer Causes Control; 2013 Jun; 24(6):1079-85. PubMed ID: 23494728
[TBL] [Abstract][Full Text] [Related]
20. Use of non-steroidal anti-inflammatory drugs and prostate cancer survival in the Finnish prostate cancer screening trial.
Veitonmäki T; Murtola TJ; Määttänen L; Taari K; Stenman UH; Tammela TL; Auvinen A
Prostate; 2015 Sep; 75(13):1394-402. PubMed ID: 26073992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]